SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LATANOPROSTENE BUNOD INITIATORS AMONG MEDICARE FEE-FOR-SERVICE PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Author(s)
Ashna Talwar, MS, PhD1, Yecheng Huang, MS2, Elizabeth Donckels, MS2, Teresa L. Brevetti, MD1, Tigwa Davis, PhD.2, Abhishek A. Nair, MS, PhD1;
1Bausch & Lomb, Somerset, NJ, USA, 2Inovalon, Bowie, MD, USA
1Bausch & Lomb, Somerset, NJ, USA, 2Inovalon, Bowie, MD, USA
OBJECTIVES: Latanoprostene bunod (LBN) is a once-daily topical prostaglandin analog approved for lowering intraocular pressure (IOP) among patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). While its dual mechanism of action offers a unique approach to IOP reduction, its positioning within glaucoma treatment algorithms, particularly as an initial therapy, remains unclear. This study aimed to identify sociodemographic and clinical characteristics of patients with OAG or OHT that initiate therapy with LBN.
METHODS: This retrospective study analyzed data from Medicare fee-for-service (Parts A, B and D) claims linked with the IRIS® Registry from January 1, 2021, through December 31, 2023. Patients were eligible if they had at least one diagnosis or treatment of OAG/OHT and IRIS-recorded IOP measurement (8-40 mmHg) within a 30-day window between January 1-December 31, 2022, and did not have any therapy during the 12-month baseline period. The index date was defined as the earliest occurrence of OAG/OHT diagnosis or treatment, or IOP assessment within this window. Sociodemographic and clinical characteristics were assessed during the 30-day window.
RESULTS: Among 150,371 treatment-naïve patients with OAG/OHT,29,911 initiated interventional therapy during the study period, and 304 patients received LBN. The cohort was predominantly female (61.8%), with a mean (SD) age of 78.4(8.3) years, and 75.7% were Caucasian. Mean (SD) index IOP was 19.0(6.0) mmHg, with 27.3% of patients exhibiting elevated IOP (>21 mmHg) and 72.7% patients with an IOP between 8-21 mmHg. Most patients had mild glaucoma (46.5%), followed by moderate glaucoma (30.8%), ocular hypertension alone (11.6%), and severe glaucoma (11.1%).
CONCLUSIONS: In this large real-world population, LBN was utilized across a range of OAG severity stages and most commonly observed among patients with baseline IOP ≤21 mmHg. This utilization pattern supports the consideration of LBN as an early therapeutic option for patients requiring effective IOP reduction, including those with normotensive glaucoma.
METHODS: This retrospective study analyzed data from Medicare fee-for-service (Parts A, B and D) claims linked with the IRIS® Registry from January 1, 2021, through December 31, 2023. Patients were eligible if they had at least one diagnosis or treatment of OAG/OHT and IRIS-recorded IOP measurement (8-40 mmHg) within a 30-day window between January 1-December 31, 2022, and did not have any therapy during the 12-month baseline period. The index date was defined as the earliest occurrence of OAG/OHT diagnosis or treatment, or IOP assessment within this window. Sociodemographic and clinical characteristics were assessed during the 30-day window.
RESULTS: Among 150,371 treatment-naïve patients with OAG/OHT,29,911 initiated interventional therapy during the study period, and 304 patients received LBN. The cohort was predominantly female (61.8%), with a mean (SD) age of 78.4(8.3) years, and 75.7% were Caucasian. Mean (SD) index IOP was 19.0(6.0) mmHg, with 27.3% of patients exhibiting elevated IOP (>21 mmHg) and 72.7% patients with an IOP between 8-21 mmHg. Most patients had mild glaucoma (46.5%), followed by moderate glaucoma (30.8%), ocular hypertension alone (11.6%), and severe glaucoma (11.1%).
CONCLUSIONS: In this large real-world population, LBN was utilized across a range of OAG severity stages and most commonly observed among patients with baseline IOP ≤21 mmHg. This utilization pattern supports the consideration of LBN as an early therapeutic option for patients requiring effective IOP reduction, including those with normotensive glaucoma.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH122
Topic
Epidemiology & Public Health
Disease
SDC: Geriatrics, SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), STA: Multiple/Other Specialized Treatments